$8.85 8.5%
EYPT Stock Price vs. AI Score (Last 150 days)
Data gathered: July 18

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc. focuses on developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders.


Eyepoint Pharmaceuticals
Price $8.85
Target Price Sign up
Volume 1,010,000
Market Cap $549M
Year Range $6 - $29.71
Dividend Yield 0%
Revenue per Employee $334,979
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q1 '2412M15M-3.2M-29M0-0.550
Q4 '2314M11M2.8M-14M-16M-0.330
Q3 '2315M11M4.2M-13M-13M-0.330
Q2 '237.3M14M-7M-23M-21M-0.610
Q1 '236.9M15M-8.1M-21M-20M-0.560

Insider Transactions View All

GUYER DAVID R filed to sell 1,850 shares at $10.1.
July 16 '24
GUYER DAVID R filed to sell 3,700 shares at $10.3.
June 4 '24
GUYER DAVID R filed to sell 5,550 shares at $12.6.
May 16 '24
Cormorant Asset Management, LP filed to buy 8,325,000 shares at $12.4.
May 8 '24
Cormorant Asset Management, LP filed to buy 8,117,847 shares at $11.7.
May 8 '24

What is the Market Cap of Eyepoint Pharmaceuticals?

The Market Cap of Eyepoint Pharmaceuticals is $549M.

How Many People Work at Eyepoint Pharmaceuticals?

As of our latest update, Eyepoint Pharmaceuticals employed approximately 144 people worldwide. However, it's important to note that Eyepoint Pharmaceuticals' workforce size can fluctuate due to the company's growth, restructuring, or strategic shifts, so the current number of employees may be different.

What is Eyepoint Pharmaceuticals' revenue per employee?

$334,979. To calculate Eyepoint Pharmaceuticals' revenue per employee, we divide the company's total revenue in the last 4 quarters by its total number of employees.

What is the current stock price of Eyepoint Pharmaceuticals?

Currently, the price of one share of Eyepoint Pharmaceuticals stock is $8.85.

How can I analyze the EYPT stock price chart for investment decisions?

The EYPT stock price chart above provides a comprehensive visual representation of Eyepoint Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Eyepoint Pharmaceuticals shares. Our platform offers an up-to-date EYPT stock price chart, along with technical data analysis and alternative data insights.

Does EYPT offer dividends to its shareholders?

As of our latest update, Eyepoint Pharmaceuticals (EYPT) does not offer dividends to its shareholders. Investors interested in Eyepoint Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Eyepoint Pharmaceuticals?

Some of the similar stocks of Eyepoint Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.